Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


QUOTED. 30 April 2020. Terri Cornelison.

Executive Summary

The US FDA will let Bayer AG roll up potentially thousands of adverse event reports about its problematic Essure birth control device into monthly spreadsheets. See what Terri Cornelison, director of the Health of Women Program within the agency’s device center, had to say about the decision.

“Even though the device is no longer being manufactured or distributed, and hasn’t been for some time, the FDA continues its engagement with Bayer on postmarket safety monitoring of Essure. Bayer alerted us to the social media information it received in connection with litigation. We are committed to ensuring that all reportable adverse events identified from this information are submitted to the agency and that they are made publicly available.” – Terri Cornelison, director,  Health of Women Program, CDRH

Click here for a free trial of Medtech Insight

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts